stoxline Quote Chart Rank Option Currency Glossary
  
Artelo Biosciences, Inc. (ARTL)
15.18  -0.89 (-5.54%)    07-16 16:00
Open: 16.61
High: 16.968
Volume: 93,180
  
Pre. Close: 16.07
Low: 15.0601
Market Cap: 8(M)
Technical analysis
2025-07-17 7:43:19 AM
Short term     
Mid term     
Targets 6-month :  23.21 1-year :  33.4
Resists First :  19.87 Second :  28.6
Pivot price 14.5
Supports First :  5.76 Second :  4.79
MAs MA(5) :  20.43 MA(20) :  12.37
MA(100) :  7.28 MA(250) :  7.16
MACD MACD :  3.3 Signal :  2.9
%K %D K(14,3) :  47.3 D(3) :  61.9
RSI RSI(14): 54.2
52-week High :  28.6 Low :  1.3
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ARTL ] has closed below upper band by 47.3%. Bollinger Bands are 599.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.99 - 17.11 17.11 - 17.2
Low: 14.78 - 14.92 14.92 - 15.04
Close: 14.98 - 15.18 15.18 - 15.33
Company Description

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Headline News

Fri, 11 Jul 2025
Artelo Biosciences Plans to Offer 920K Shares of Common Stock - AInvest

Wed, 09 Jul 2025
Artelo Biosciences Soars 30.5% on Promising Depression Drug Data - AInvest

Wed, 09 Jul 2025
Artelo Biosciences Presents Preclinical Data on ART26.12 as Potential Non-Opioid Treatment for Osteoarthritis Pain at ICRS Symposium - Quiver Quantitative

Wed, 09 Jul 2025
Artelo Biosciences’ ART12.11 Shows Promising Antidepressant Effects in Preclinical Study - Yahoo Finance

Mon, 07 Jul 2025
Dow Dips 1%; Mustang Bio Shares Spike Higher - Benzinga

Mon, 07 Jul 2025
Artelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression Drug - Stocktwits

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 0.8 (%)
Held by Institutions 2.6 (%)
Shares Short 12 (K)
Shares Short P.Month 57 (K)
Stock Financials
EPS -17.95
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.19
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -89.3 %
Return on Equity (ttm) -190.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio -0.85
PEG Ratio 0
Price to Book value 12.75
Price to Sales 0
Price to Cash Flow -1.19
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android